MEI Pharma, Inc.

9920 Pacific Heights Blvd., Suite 150

San Diego, CA 92121

September 3, 2025

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tim Buchmiller, Esq.

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-289312), so that such registration statement may become effective at 4:30 p.m. (Washington, D.C. time) on September 5, 2025, or as soon as practicable thereafter.

MEI PHARMA, INC.


By:        /s/ Justin J. File                                         
Name:   Justin J. File
Title:     Acting Chief Executive Officer